Genetic predispositions (e.g., PNPLA3 and TM6SF2 polymorphisms) and epigenetic modifications (e.g., altered microRNA profiles) further modulate individual susceptibility and disease trajectory
The most widely used GLP-1 RAs today and those currently attributed with the most clinical evidence in weight management include Liraglutide, Semaglutide, and Tirzepatide (as a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide) [25]
Some people experience a minor increase in nausea or reflux as the medication levels peak again
No peptide protocol should begin without baseline labs, and follow-up testing is what tells you whether it is working
Los medicamentos agonistas del receptor del pptido similar al glucagn tipo 1 (GLP-1) son una clase de frmacos inyectables utilizados principalmente para el tratamiento de la diabetes tipo 2 y, en algunos casos, para el manejo del peso
Ann Clin Transl Neurol 2025